Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110215 · Präparat HOS-093339
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors
such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole
antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such
as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib
concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of
imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a
single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering
Glivec with inhibitors of the CYP3A4 family.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Revolade
Revolade 12.5 mg film-coated tablets Revolade 25 mg film-coated tablets Revolade 50 mg film-coated tablets Revolade 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-122076 · Präparat HOS-095473
Dose adjustment is not required when eltrombopag is co-administered with either telaprevir or
boceprevir. Co-administration of a single dose of eltrombopag 200 mg with telaprevir 750 mg every
8 hours did not alter plasma telaprevir exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): telaprevir (HOS-090618) boceprevir (HOS-090617)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage a6f1fd5c4215a5e1769c2983333eb0a83a9289ec4b9f7f33a76357f2306a299b · Zeichen 1597–1838 im Abschnitt
Wechselwirkungen · Revolade
Revolade 12.5 mg film-coated tablets Revolade 25 mg film-coated tablets Revolade 50 mg film-coated tablets Revolade 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-122096 · Präparat HOS-095473
Results of a drug-drug pharmacokinetic (PK) interaction study show that co-administration of repeat
doses of boceprevir 800 mg every 8 hours or telaprevir 750 mg every 8 hours with a single dose of
eltrombopag 200 mg did not alter plasma eltrombopag exposure to a clinically significant extent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): telaprevir (HOS-090618) boceprevir (HOS-090617)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 3fa1bbd8780cc3ea77fe92e3ca3bdf19e7d9544725bdaef44f0727bcdaace54f · Zeichen 4854–5148 im Abschnitt
Wechselwirkungen · Revolade
Revolade 25 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 53
HOS-122161 · Präparat HOS-095473
Dose adjustment is not required when eltrombopag is co-administered with either telaprevir or
boceprevir. Co-administration of a single dose of eltrombopag 200 mg with telaprevir 750 mg every
8 hours did not alter plasma telaprevir exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): telaprevir (HOS-090618) boceprevir (HOS-090617)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage a6f1fd5c4215a5e1769c2983333eb0a83a9289ec4b9f7f33a76357f2306a299b · Zeichen 1653–1894 im Abschnitt
Wechselwirkungen · Revolade
Revolade 25 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 54
HOS-122172 · Präparat HOS-095473
Results of a drug-drug pharmacokinetic (PK) interaction study show that co-administration of repeat
doses of boceprevir 800 mg every 8 hours or telaprevir 750 mg every 8 hours with a single dose of
eltrombopag 200 mg did not alter plasma eltrombopag exposure to a clinically significant extent.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): telaprevir (HOS-090618) boceprevir (HOS-090617)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 3fa1bbd8780cc3ea77fe92e3ca3bdf19e7d9544725bdaef44f0727bcdaace54f · Zeichen 4910–5204 im Abschnitt
Wechselwirkungen · Zoely
Zoely 2.5 mg/1.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-123116 · Präparat HOS-095645
Hepatic metabolism: Interactions can occur with substances that induce CYP450 enzymes, resulting in
reduced concentrations of sex hormones and decreased effectiveness of combined oral contraceptives,
including Zoely. These substances are represented mostly with anticonvulsants (e.g. carbamazepine,
topiramate, phenytoin, phenobarbital, primidone, oxcarbazepine, felbamate); anti-infective drugs (e.g.
rifampicin, rifabutin, griseofulvin); St. John’s wort; bosentan and HIV or Hepatitis C virus (HCV)
protease inhibitors (e.g. ritonavir, boceprevir, telaprevir) and non-nucleoside reverse transcriptase
inhibitors (e.g. efavirenz).
Enzyme induction can occur after a few days of treatment. Maximal enzyme induction is generally
11
observed within a few weeks. After drug therapy is discontinued, enzyme induction can last for about
28 days.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): felbamate (HOS-110308) protease (HOS-085623) topiramate (HOS-110310) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) hepatitis C virus (HOS-108813) telaprevir (HOS-090618) boceprevir (HOS-090617) griseofulvin (HOS-091156) efavirenz (HOS-087947) oxcarbazepine (HOS-110224) ritonavir (HOS-084521) bosentan (HOS-086291) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-19T01:25:00Z · SHA-256 dc49cf8021f816c4c7a796f72b78aa51d7e7cdb416565d60506c315b6ddcb3e2 · Passage f5dcfc8d38c2cd7a898cac819176553092ce45a5a5a7f2de510ba2c6181b7ca9 · Zeichen 330–1223 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-215280 · Präparat HOS-155418
10
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
(dose) Cmax, Cmin with confidence efavirenz
intervals if availablea
(mechanism)
Cmin: ↓ 44% reduction of boceprevir trough
Efavirenz: concentrations has not been
AUC: ↔ 20% directly assessed.
Cmax: ↔ 11%
(CYP3A induction - effect on
boceprevir)
*0-8 hours
No effect (↔) equals a decrease in
mean ratio estimate of ≤20% or
increase in mean ratio estimate of
≤25%
Telaprevir/efavirenz Telaprevir (relative to If efavirenz and telaprevir are co-
(1,125 mg q8h/600 mg once 750 mg q8h): administered, telaprevir 1,125 mg
daily) AUC: ↓ 18% (↓ 8 to ↓ 27) every 8 hours should be used.
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmin: ↓ 25% (↓ 14 to ↓ 34)%
Efavirenz:
AUC: ↓ 18% (↓ 10 to ↓ 26)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmin: ↓ 10% (↑ 1 to ↓ 19)%
(CYP3A induction by efavirenz)
Simeprevir/efavirenz Simeprevir: Concomitant administration of
(150 mg once daily /600 mg once AUC: ↓71% (↓67 to ↓74) simeprevir with efavirenz resulted
daily) Cmax: ↓51% (↓46 to ↓56) in significantly decreased plasma
concentrations of simeprevir due
Cmin: ↓91% (↓88 to ↓92)
to CYP3A induction by efavirenz,
Efavirenz: which may result in loss of
AUC: ↔ therapeutic effect of simeprevir.
Cmax: ↔ Co-administration of simeprevir
Cmin: ↔ with efavirenz is not
No effect (↔) equals a decrease in recommended.
mean ratio estimate of ≤20% or
increase in mean ratio estimate of
≤25%
(CYP3A4 enzyme induction)
Sofosbuvir/velpatasvir ↔sofosbuvir Concomitant administration of
↓velpatasvir sofosbuvir/velpatasvir with
efavirenz resulted in a
↔efavirenz
reduction (approximately
50%) in the systemic exposure
of velpatasvir. The mechanism
of the effect on velpatasvir is
induction of CYP3A and
CYP2B6 by efavirenz.
Coadministration of
sofosbuvir/velpatasvir with
efavirenz is not recommended.
Refer to the prescribing
information for
sofosbuvir/velpatasvir for
more information.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) telaprevir (HOS-090618) boceprevir (HOS-090617) velpatasvir (HOS-108929) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage baf3de0ce331552ab4e8a0d66b808da705c2aa678bebe78ae93bc0e3a2c80fc0 · Zeichen 18844–23796 im Abschnitt
Wechselwirkungen · Bosulif
Bosulif 100 mg film-coated tablets Bosulif 400 mg film-coated tablets Bosulif 500 mg film-coated tablets Bosulif 50 mg hard capsules Bosulif 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-125439 · Präparat HOS-096073
CYP3A inhibitors
The concomitant use of bosutinib with strong CYP3A inhibitors (including, but not limited to
itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, nefazodone,
mibefradil, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir,
grapefruit products including grapefruit juice) or moderate CYP3A inhibitors (including, but not
limited to fluconazole, ciprofloxacin, erythromycin, diltiazem, verapamil, amprenavir, atazanavir,
darunavir/ritonavir, fosamprenavir, aprepitant, crizotinib, imatinib) should be avoided, as an increase
in bosutinib plasma concentration will occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) diltiazem (HOS-086288) nefazodone (HOS-084519) lopinavir (HOS-086269) atazanavir (HOS-086180) nelfinavir (HOS-084520) ciprofloxacin (HOS-085177) ketoconazole (HOS-084513) crizotinib (HOS-116818) aprepitant (HOS-112506) mibefradil (HOS-125440) grapefruit juice (HOS-088787) imatinib (HOS-110212) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) amprenavir (HOS-086183) darunavir (HOS-086181) fosamprenavir (HOS-086182) ritonavir (HOS-084521) posaconazole (HOS-085622) bosutinib (HOS-109449) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-12T15:15:00Z · SHA-256 86c38605c3386630b4591643bb4507bc13ee17f96b594c991ef48865ec55c6c0 · Passage bf891fc27dae495286d0ddabf1a684337d5b862d791c1636c6fade4c46be3a59 · Zeichen 50–707 im Abschnitt
Wechselwirkungen · Jakavi
Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-126103 · Präparat HOS-096217
CYP3A4 inhibitors
Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir,
itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir,
posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4
inhibitor, ketoconazole, resulted in ruxolitinib Cmax and AUC that were higher by 33% and 91%,
respectively, than with ruxolitinib alone. The half-life was prolonged from 3.7 to 6.0 hours with
concurrent ketoconazole administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) lopinavir (HOS-086269) nelfinavir (HOS-084520) ketoconazole (HOS-084513) mibefradil (HOS-125440) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T13:51:00Z · SHA-256 f5e9d15f087df0766ff15826906abe609cecf3c8ef177236024d00e93ae36c17 · Passage d329ec62a597a37f210747cb5936529e376d106c5b40c5806cb929da50c9327c · Zeichen 291–892 im Abschnitt
Wechselwirkungen · Jakavi
Jakavi 5 mg/ml oral solution · Abschnitt 4.5 · PDF-Seite 42
HOS-126197 · Präparat HOS-096217
CYP3A4 inhibitors
Strong CYP3A4 inhibitors (such as, but not limited to, boceprevir, clarithromycin, indinavir,
itraconazole, ketoconazole, lopinavir/ritonavir, ritonavir, mibefradil, nefazodone, nelfinavir,
posaconazole, saquinavir, telaprevir, telithromycin, voriconazole)
In healthy subjects co-administration of ruxolitinib (10 mg single dose) with a strong CYP3A4
inhibitor, ketoconazole, resulted in ruxolitinib Cmax and AUC that were higher by 33% and 91%,
respectively, than with ruxolitinib alone. The half-life was prolonged from 3.7 to 6.0 hours with
concurrent ketoconazole administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) lopinavir (HOS-086269) nelfinavir (HOS-084520) ketoconazole (HOS-084513) mibefradil (HOS-125440) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-10T13:51:00Z · SHA-256 f5e9d15f087df0766ff15826906abe609cecf3c8ef177236024d00e93ae36c17 · Passage d329ec62a597a37f210747cb5936529e376d106c5b40c5806cb929da50c9327c · Zeichen 291–892 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-126950 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir/ pibrentasvir (see section 4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoprofen (HOS-089671) nefazodone (HOS-084519) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage 01cd865d152730ea7f87e81073b6bc3ccb3f2ff3a9e8e7ee83649a48ba092bdb · Zeichen 0–1506 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/40 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 25
HOS-127022 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir, pibrentasvir, elbasvir or grazoprevir (see section
4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Concomitant administration of amiodarone, verapamil, amlodipine or diltiazem (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoprofen (HOS-089671) nefazodone (HOS-084519) elbasvir (HOS-108814) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) amlodipine (HOS-086287) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage b3e383eea6addd5e17e74e7e066bd16291ed5af47e0e656fd20c321af353dadc · Zeichen 0–1610 im Abschnitt
Gegenanzeigen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-128649 · Präparat HOS-096607
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Concomitant administration of strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin,
cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole,
ritonavir, saquinavir, telaprevir, telithromycin, voriconazole) and strong CYP3A4 inducers (e.g.
carbamazepine, phenobarbital, phenytoin, rifampicin, St John’s wort (Hypericum perforatum)
(see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) cobicistat (HOS-088111) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) phenytoin (HOS-084531) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage f4f897bb576a76ba279564ebc41b3c0ed933513149ec679495bda200554c30cb · Zeichen 0–512 im Abschnitt
Wechselwirkungen · Latuda
Latuda 18.5 mg film-coated tablets Latuda 37 mg film-coated tablets Latuda 74 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-128663 · Präparat HOS-096607
CYP3A4 inhibitors
Lurasidone is contraindicated with strong CYP3A4 inhibitors (e.g. boceprevir, clarithromycin,
cobicistat, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir,
saquinavir, telaprevir, telithromycin, voriconazole) (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) cobicistat (HOS-088111) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T16:17:00Z · SHA-256 1b4eb934eea6c777e082db5accb51f11c854318bf5d2d82b61249264a6b6a684 · Passage 09ceff85d6e3597d91081f1ae70def38e33604e565fd12240ad9751189d77354 · Zeichen 1515–1798 im Abschnitt
Wechselwirkungen · Reagila
Reagila 1.5 mg hard capsules Reagila 3 mg hard capsules Reagila 4.5 mg hard capsules Reagila 6 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-129547 · Präparat HOS-096751
CYP3A4 inhibitors
Ketoconazole, a strong CYP3A4 inhibitor, caused two-fold increase in plasma exposure for total
cariprazine (sum of cariprazine and its active metabolites) during short-term (4 days)
co-administration, either if unbound or unbound+bound moieties considered.
Due to the long half-life of the active moieties of cariprazine a further increase in plasma exposure of
total cariprazine can be expected during longer co-administration. Therefore, co-administration of
cariprazine with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, cobicistat, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir,
telithromycin, voriconazole) is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) cobicistat (HOS-088111) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T14:49:00Z · SHA-256 9d13d908e239f6368505bfcde6e4381ffb6295f6bc6de049f006e4abed967ec2 · Passage f9f3fc43a4759427217ea54bfc6c9fe0f0b5a5f5280d255b3e3faf401d0a64e6 · Zeichen 255–1001 im Abschnitt
Wechselwirkungen · Reagila
Reagila 1.5 mg orodispersible tablets Reagila 3 mg orodispersible tablets Reagila 4.5 mg orodispersible tablets Reagila 6 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 24
HOS-129581 · Präparat HOS-096751
CYP3A4 inhibitors
Ketoconazole, a strong CYP3A4 inhibitor, caused two-fold increase in plasma exposure for total
cariprazine (sum of cariprazine and its active metabolites) during short-term (4 days)
co-administration, either if unbound or unbound+bound moieties considered.
Due to the long half-life of the active moieties of cariprazine a further increase in plasma exposure of
total cariprazine can be expected during longer co-administration. Therefore, co-administration of
cariprazine with strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, cobicistat, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir,
telithromycin, voriconazole) is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) nefazodone (HOS-084519) nelfinavir (HOS-084520) ketoconazole (HOS-084513) cobicistat (HOS-088111) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T14:49:00Z · SHA-256 9d13d908e239f6368505bfcde6e4381ffb6295f6bc6de049f006e4abed967ec2 · Passage f9f3fc43a4759427217ea54bfc6c9fe0f0b5a5f5280d255b3e3faf401d0a64e6 · Zeichen 255–1001 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.